EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Non‐discontinuation of antiseizure medication in seizure‐free patients with epilepsy: Reasons and predictors among neurologists and patients

Maria Ilyas-Feldmann iD, Luise Graf iD, Jakob I Doerrfuss iD, Matthias Dipper-Wawra iD, Nicoletta Doerr, Rebekka Lehmann, Christian Meisel iD, David Steinbart iD, Mirja Steinbrenner iD, Martin Holtkamp iD

Epilepsia · 2025

DOI: 10.1111/epi.18519 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Epilepsia, 2025. Verfasst von Maria Ilyas-Feldmann und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology with Experimental Neurology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Un…. Hauptthemen laut MEDLINE: Anticonvulsants, Neurologists, Epilepsy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of Neurology, Charité- Universitätsmedizin Berlin, Department of Neurology, College of Medicine, Medical University of South Carolina.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study was undertaken to investigate clinical and psychosocial factors associated with antiseizure medication (ASM) non‐discontinuation in seizure‐free patients with epilepsy among both neurologists and patients.

Methods

In this cross‐sectional study, neurologists documented their recommendations on ASM discontinuation (comprising both complete discontinuation and ≥25% dose reduction) in patients aged ≥18 years who had been seizure‐free for at least 2 years. Based on these recommendations, patients made individual decisions. In both neurologists and patients, reasons for and predictors of ASM non‐discontinuation were assessed considering demographic and epilepsy‐related variables as well as standardized psychosocial questionnaires.

Results

Among 196 patients (53.1% female, median age = 50 years, interquartile range [IQR] = 36–61; median seizure‐free duration = 6 years, IQR = 4–11), neurologists recommended ASM discontinuation in 110 cases (56.1%), of which 29 patients (26.4%) agreed. Neurologists were more likely to favor ASM non‐discontinuation if they had fewer years of professional experience (odds ratio [OR] = .96, 95% confidence interval [CI] = .92–.99) and if patients had shorter seizure‐free durations (OR = .98, 95% CI = .98–.99). Among patients, longer seizure‐free duration (OR = 1.01, 95% CI = 1.01–1.02) and a history of generalized or focal to bilateral tonic–clonic seizures (OR = 2.72, 95% CI = 1.15–6.43) were independently associated with ASM non‐discontinuation. Excluding the 27 patients who favored a dose reduction, ASM non‐discontinuation was still associated with a longer duration of seizure freedom (OR = 1.02, 95% CI = 1.01–1.03). Further predictors were higher anxiety scores (OR = 1.37, 95% CI = 1.05–1.78) and better ASM tolerability (OR = 1.04, 95% CI = 1.01–1.07). Significance Neurologists and, even more so, patients are hesitant to discontinue ASM, which was accomplished in only 15% of seizure‐free patients. Duration of seizure freedom has a major impact on the decision but in opposite directions comparing both groups. Understanding these differing perspectives is essential to improve shared decision‐making on this complex issue in epilepsy care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticonvulsantsNeurologistsEpilepsyHumansFemaleMaleAdultMiddle AgedCross-Sectional StudiesSurveys and Questionnaires

Stichwörter der Autor:innen

drug withdrawaloutcomepharmacotherapyseizure freedomseizure recurrence risk

Substanzen

Anticonvulsants

Autor:innen und Institutionen

  • Department of Neurology with Experimental Neurology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität Zu Berlin, Berlin, Germany.
  • Epilepsy Center Berlin-Brandenburg, Institute for Diagnostics of Epilepsy, Berlin, Germany.

ORCID-Profile: Maria Ilyas-Feldmann, Luise Graf, Jakob I Doerrfuss, Matthias Dipper-Wawra, Christian Meisel, David Steinbart, Mirja Steinbrenner, Martin Holtkamp

Förderung

  • Department of Neurology, Charité- Universitätsmedizin Berlin
  • Department of Neurology, College of Medicine, Medical University of South Carolina

Zitieren

APA

Ilyas-Feldmann, M., Graf, L., Doerrfuss, J. I., Dipper-Wawra, M., Doerr, N., Lehmann, R., Meisel, C., Steinbart, D., Steinbrenner, M., & Holtkamp, M. (2025). Non‐discontinuation of antiseizure medication in seizure‐free patients with epilepsy: Reasons and predictors among neurologists and patients. Epilepsia. https://doi.org/10.1111/epi.18519

Vancouver

Ilyas-Feldmann M, Graf L, Doerrfuss JI, Dipper-Wawra M, Doerr N, Lehmann R, et al. Non‐discontinuation of antiseizure medication in seizure‐free patients with epilepsy: Reasons and predictors among neurologists and patients. Epilepsia. 2025. doi:10.1111/epi.18519

BibTeX
@article{IlyasFeldmann2025,
  author = {Ilyas-Feldmann, Maria and Graf, Luise and Doerrfuss, Jakob I and Dipper-Wawra, Matthias and Doerr, Nicoletta and Lehmann, Rebekka and Meisel, Christian and Steinbart, David and Steinbrenner, Mirja and Holtkamp, Martin},
  title = {Non‐discontinuation of antiseizure medication in seizure‐free patients with epilepsy: Reasons and predictors among neurologists and patients},
  journal = {Epilepsia},
  year = {2025},
  doi = {10.1111/epi.18519}
}
Kostenlos starten →